ÍøºìºÚÁÏ

Skip to main content

John A Ligon, MD : Research

Pediatric Hematologist/Oncologist (Child Cancer Specialist)

Photo of John A Ligon

Research at a glance

Top areas of exploration

  • Neoplasms , 4 publications
  • Cell Line, Tumor , 2 publications
  • Bone Neoplasms , 2 publications
  • Immunocompromised Host , 2 publications

Research activity

38 publications

454 citations

Why is this important?

Active clinical trials

Tinks Trial

The purpose of this study is to determine if the addition of infusions of a type of immune cell called a "natural killer", or NK cell to the sarcoma chemotherapy regimen GEM/DOX (gemcitabine and docetaxel) can improve outcomes in people with…

Investigator
John A Ligon
Status
Accepting Candidates
Ages
2 Years - 40 Years
Sexes
All
OMS721-HCT-002

The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).

Investigator
John A Ligon
Status
Accepting Candidates
Ages
28 Days - 17 Years
Sexes
All

My publications

38 publications

2023

A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma

Clinical Cancer Research

2023

Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions

Acta Biomaterialia

2023

Emerging frontiers in immuno- and gene therapy for cancer

Cytotherapy

•

2023

Mediport use as an acceptable standard for CAR T cell infusion.

Frontiers in immunology

•

2023

mRNA aggregates harness danger response for potent cancer immunotherapy.

medRxiv : the preprint server for health sciences

•